Unitaid audited financial report for the year ended 31 December 2022
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Overview of mpox antivirals and diagnostics landscape
Next generation pulse oximeters technology and market landscape
Malaria diagnostics market and technology landscape
Landscape of innovative tools and delivery strategies for eliminating vertical transmission of HIV, syphilis, hepatitis B, and chagas in endemic areas
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Cervical cancer. Screening and treatment of pre-cancerous lesions for secondary prevention of cervical cancer
The state of the malaria RDT market 2018
Knowing your status – then and now. Realizing the potential of HIV self-testing, STAR Initiative Report
Intellectual property report on long-acting technologies
Market and technology landscape: HIV rapid diagnostic tests for self-testing, 4th edition
Global malaria diagnostic and artemisinin treatment commodities demand forecast: 2017 – 2021 Policy brief (May 2018)
Global malaria diagnostic and artemisinin treatment commodities demand forecast: 2017 – 2021 Report (May 2018)
Global malaria diagnostic and artemisinin treatment commodities demand forecast: 2017 – 2021 Policy brief (May 2018)
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
Safeguarding – supplemental annex to Unitaid wrongdoing guidelines
FAQ – Financial Guidelines
Guidelines prevention, reporting and management of wrongdoing
Impact story: Expanding access to next generation drug-resistant tuberculosis treatment
Unitaid’s Impact 2017 Results and Key Performance Indictors
